Choosing Health Before Pregnancy Begins
Preimplantation Genetic Testing (PGT) is an advanced embryo screening technique performed during IVF. It allows our scientists to analyse the genetic makeup of embryos before transfer, helping to identify the healthiest ones and reduce the risk of inherited conditions, chromosomal abnormalities, and miscarriage.
How PGT Works
A biopsy of 5-10 cells is taken from each embryo at the blastocyst stage. These cells are analysed by a specialist genetics laboratory. PGT-A screens for chromosomal number abnormalities. PGT-M screens for specific single-gene disorders such as cystic fibrosis or BRCA mutations. PGT-SR is used when one or both partners carry a chromosomal structural rearrangement.
Key Benefits of Preimplantation Genetic Testing (PGT)
- Identifies chromosomally normal embryos before transfer
- Reduces the risk of miscarriage
- Screens for specific inherited genetic conditions (PGT-M)
- Suitable for carriers of chromosomal rearrangements (PGT-SR)
- Can improve live birth rates per transfer cycle
Who Is a Good Candidate for Preimplantation Genetic Testing (PGT)?
- Women aged 35 and over
- Couples with recurrent miscarriage
- Carriers of hereditary genetic conditions
- Those with previous failed IVF cycles
- Couples with known chromosomal structural rearrangements
PGT Treatment Timeline
Before Cycle
Genetic counselling and probe design (for PGT-M/SR). Takes 4-8 weeks in advance.
Day 1-12
Ovarian stimulation and monitoring. Egg retrieval at optimal time.
Day 5-6
Embryos biopsied at blastocyst stage. Vitrified while awaiting genetic results.
Week 1-3
PGT results received. Unaffected, normal embryos identified for transfer.
FET Cycle
Endometrial preparation. Transfer of the selected healthy embryo.
2 Weeks Post-Transfer
Pregnancy test. Prenatal screening recommended to continue monitoring.
Frequently Asked Questions About PGT
PGT-A tests for chromosomal count abnormalities. PGT-M tests for a specific inherited gene mutation. PGT-SR is for couples where one partner carries a structural chromosomal change such as a translocation.
PGT significantly reduces the risk of certain abnormalities, but no test can guarantee a completely healthy outcome. Routine prenatal screening is still recommended during pregnancy.
The biopsy is performed by expert embryologists at the blastocyst stage. Survival rates are very high, and normal embryos are unaffected in their developmental potential.
Results are typically available within 1-3 weeks. PGT-M requires additional preparation of 4-8 weeks before the IVF cycle can begin.